Compass Pathways Adds Veteran HR Executive as FDA Nod Nears — Compass Pathfinder Limited

Event summary

Kelley Boucher appointed Chief People Officer at Compass Pathways, effective September 30, 2026.
Boucher brings 20+ years of HR leadership experience in biotech, including roles at Apellis and Alnylam.
Appointment timed ahead of planned NDA submission for COMP360 psilocybin in Q4 2026.
Focus on scaling team for potential commercial launch in H1 2027, pending FDA approval.

The big picture

Compass Pathways' appointment of Kelley Boucher as Chief People Officer underscores the company's focus on operational readiness ahead of a potential FDA approval for its psilocybin-based treatment. The move reflects broader industry trends where biotech firms prioritize talent strategy as they pivot from clinical development to commercialization. With COMP360 psilocybin poised to become a first-in-class treatment, Compass is positioning itself to capitalize on the growing demand for innovative mental health solutions.

What we're watching

Regulatory Timing: Whether Compass can maintain its aggressive timeline for FDA approval and commercial launch.
Team Scaling: How effectively Boucher can prepare the organization for the transition from clinical to commercial operations.
Market Readiness: The pace at which Compass can establish commercial infrastructure for psilocybin-based treatments.